Real-World Data from Italy: Luspatercept Shows Promise in Transfusion-Dependent Beta-Thalassemia
Mostafa Faisal, associate professor of Adult Hematology and BMT, recently shared a post on use of Luspatercept on X:
”Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy – The American Journal of Hematology.”
Read the full article here.
Following the approval of the drug in the U.S. and Europe—based on the findings of the randomized, placebo-controlled phase III BELIEVE trial—there remained a need to generate robust real-world evidence on its effectiveness, safety, and tolerability in routine clinical settings.
To address this, the impact of luspatercept treatment in a cohort of 231 individuals with TDT was assessed.
Published in the American Journal of Hematology, this new study presents one of the largest real-world cohorts examining the use of the drug in patients with transfusion-dependent beta-thalassemia (TDT) across Italy.
To learn more on new scientific advances in hematology, read Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly